Anixa Biosciences, Inc. income statement ANIX

Annual Quarterly

It recorded a net loss of $10.9 million. Diluted earnings per share were -$0.34. Across the 7 fiscal years shown, revenue shrank from $9.3 million in fiscal 2015 to $210,000 in fiscal 2024, about 46.8% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2025 Oct 31, 2025	FY 2024 Oct 31, 2024	FY 2023 Oct 31, 2023	FY 2022 Oct 31, 2022	FY 2022 Oct 31, 2021	FY 2020 Oct 31, 2020	FY 2018 Oct 31, 2018	FY 2017 Oct 31, 2017	FY 2016 Oct 31, 2016	FY 2015 Oct 31, 2015
Revenue	—	0	0 -59.0%	—	1	—	1 +206.9%	0 +20.8%	0 -96.8%	9 +152.4%
Research and development	5 -20.7%	6 +34.1%	5 -23.0%	7	6	4 -20.0%	7 +326.5%	2 +2.6%	2	—
Selling, general and administrative	7 -10.8%	7 +18.2%	6 -11.1%	7	7	6 -1.2%	7 +56.7%	4 +62.8%	3 -50.9%	6 -14.0%
Operating income	-12 +15.4%	-14 -25.6%	-11 +16.2%	-14	-13	-10 +16.1%	-14 -135.2%	-6 -34.7%	-5 -377.3%	-1 +81.3%
Pretax income	—	—	—	—	—	—	-14 -184.4%	-5 +0.1%	-5 -263.8%	-1 +85.6%
Net income	-11 +13.0%	-13 -28.0%	-10 +24.3%	-14	-13	-10	-14 -179.4%	-5 +0.1%	-5 -263.8%	-1 +85.6%
Basic EPS	-0.34 +12.8%	-0.39 -21.9%	-0.32 -171.1%	0.45	—	—	—	—	—	—
Diluted EPS	-0.34 +12.8%	-0.39 -21.9%	-0.32	—	—	—	—	—	—	—
Weighted average shares, basic	0 +1.7%	0 +3.0%	0	—	—	—	—	—	—	—
Weighted average shares, diluted	0 +1.7%	0 +3.0%	0 +2.0%	0	—	—	—	—	—	—
Other measures
Depreciation and amortization	—	—	—	0	0	—	—	—	—	—
EBITDA	—	—	—	-14	-13	—	—	—	—	—
Interest coverage	—	—	—	—	—	—	-28.55x	—	-8.67x	-2.09x
Margins
Operating margin	—	-6,586.19%	-5,243.33%	—	-2,565.62%	—	-1,284.41%	-1,676.02%	-1,503.00%	-10.21%
Pretax margin	—	—	—	—	—	—	-1,280.28%	-1,381.79%	-1,672.14%	-14.90%
Profit margin	—	-5,978.10%	-4,671.90%	—	-2,530.08%	—	-1,258.07%	-1,381.79%	-1,672.14%	-14.90%
EBITDA margin	—	—	—	—	-2,558.15%	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: ANIX (Nasdaq)
Fiscal year ends: October 31
Incorporated in: DE
Headquarters: San Jose, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 715446
Former names: ITUS Corp (until Sep 27, 2018); COPYTELE INC (until Aug 27, 2014)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.